GSK has acquired the rights to Syndivia’s preclinical antibody drug conjugate (ADC), which is in development for prostate ...
The National Institute for Health and Care Excellence (NICE) has recommended darolutamide in combination with androgen ...
GSK said it acquired exclusive worldwide rights for a drug candidate targeting prostate cancer from France's Syndivia for up to 268 million pounds ($356.8 million).
The combination of niraparib and abiraterone halves the spread of prostate cancer in men with BRCA gene mutations.
Prostate cancer screening for men over 70 is complex, with current recommendations against routine PSA testing due to slow ...
Phase 3 ARENSENS clinical trial results were presented at JADPRO 2025, indicating darolutamide plus ADT improved rPFS in prostate cancer.
The Healthy @Reader's Digest on MSN
New Prostate Cancer Treatment Options You Should Know About, From a Urologic Surgeon
A globally-renowned prostate cancer surgeon shares the latest advancements in the field and stresses the importance of early ...
Enzalutamide plus leuprolide reduces the risk of death by more than 40% in biochemically recurrent prostate cancer compared to leuprolide alone.
The 2025 edition of the European Society for Medical Oncology(ESMO) was held this week in Berlin, delve into its key ...
NICE recommendation of darolutamide plus hormone therapy for metastatic prostate cancer offers around 6000 patients in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback